CRISPR/Cas13 based biosensing of miRNA-21 as a diagnostic biomarker for Alzheimer's disease
OA Version
Citation
Abstract
Alzheimer’s Disease is one of the most prevalent neurodegenerative diseases affecting the elderly population, with approximately 65 million individuals diagnosed worldwide. The hallmark pathological features include the accumulation of Aß senile plaques and the hyperphosphorylation of tau protein, ultimately leading to memory loss, cognitive deficits and loss of executive function. Due to its rapid progression and the inability to diagnose in early stages, mechanisms for detection and target biomarkers for AD have been well under study. In recent years, small extracellular vesicles, also known as exosomes, which contain a variety of macromolecules: protein, RNA, lipids and other metabolites, have been capable of acting as biomarkers for a wide variety of cancers and other diseases due to their ability to reflect the physiological status of the origin cell. This study will aim to characterize the presence of microRNA-21, a potential biomarker for AD, in SH-SY5Y neuroblastomal-derived exosomes using the CRISPR/Cas13 (Clustered Regularly Interspaced Short Palindromic Repeats) platform for diagnostic assay.
Description
2024